Jean-Paul Kress
Chief Executive Officer bei MORPHOSYS AG
Vermögen: - $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Laurence J. Blumberg | M | 62 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 11 Jahre |
| Marc Cluzel | M | 69 | 12 Jahre | |
| Seth Harrison | M | 63 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Günter Wellnhofer | M | - | 30 Jahre | |
| Luisa Ciccarelli | F | - | 3 Jahre | |
| Joseph Bratica | M | 60 | 7 Jahre | |
| Richard S. Blumberg | M | - |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 11 Jahre |
| Daniel Palmacci | M | - | 4 Jahre | |
| Andrew Cheng | M | 57 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 2 Jahre |
| Benoît Gueugnon | M | - | 6 Jahre | |
| Krisja Vermeylen | F | 62 | 7 Jahre | |
| Julia Neugebauer | M | - | 18 Jahre | |
| Ann Merchant | F | 59 | 6 Jahre | |
| Isabelle Degbegni | F | - | - | |
| Robert Mayer | M | - | 3 Jahre | |
| Tim Demuth | M | 50 | 2 Jahre | |
| Lucinda Crabtree | M | 45 | 1 Jahre | |
| Jake Elkins | M | - | 7 Jahre | |
| Thomas Biegi | M | - | 4 Jahre | |
| Sharon Curran | F | 56 | 5 Jahre | |
| Anabella Villalobos | M | 65 | 7 Jahre | |
| Ralf Ostendorp | M | - | 25 Jahre | |
| Klaus de Wall | M | - | 19 Jahre | |
| Barbara Krebs-Pohl | M | - | 26 Jahre | |
| Ginger Gregory | M | 56 | 7 Jahre | |
| Charlotte Lohmann | F | 54 | 12 Jahre | |
| George Golumbeski | M | 67 | 6 Jahre | |
| Michael Brosnan | M | 69 | 6 Jahre | |
| Eamonn Nolan | M | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Goolsbee | M | 70 | 9 Jahre | |
| David de Graaf | M | - |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Jeffrey Capello | M | 69 | 3 Jahre | |
| Melanie Rolli | M | 51 |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 Jahre |
| Roland Wandeler | M | 51 | 1 Jahre | |
| Didier Hoch | M | 68 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | - |
| Luc Dochez | M | 49 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 8 Jahre |
| Christophe Jurczak | M | - |
École Normale Supérieure
| 3 Jahre |
| Anne Bouverot | M | 58 |
École Normale Supérieure
| 3 Jahre |
| Ben Price | M | 68 | 9 Jahre | |
| Allene Diaz | F | 59 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 Jahre |
| Paul Clancy | M | 62 | 16 Jahre | |
| Frank Morich | M | 69 | 5 Jahre | |
| Chirfi Guindo | M | 58 | 5 Jahre | |
| Malte Peters | M | 61 | 5 Jahre | |
| Wendy Johnson | F | 72 | 7 Jahre | |
| Sven Arne Andréasson | M | 72 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 14 Jahre |
| Simon Moroney | M | 65 | 27 Jahre | |
| Michael Halpin | M | 62 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 Jahre |
| Markus Enzelberger | M | 55 | 18 Jahre | |
| Arun Padmanabhan | M | - | 3 Jahre | |
| Michael Mano | M | 47 | 2 Jahre | |
| Mark Hernon | M | - | 4 Jahre | |
| Adriana Bokel Herde | F | - | 6 Jahre | |
| Alpna Seth | M | 60 | 3 Jahre | |
| Jason Hoitt | M | 46 | 4 Jahre | |
| Nia Tatsis | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 Jahre |
| Robin A. Walker | M | 55 | 8 Jahre | |
| Kenneth DiPietro | M | 65 | 5 Jahre | |
| Adam Hansard | M | 48 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 1 Jahre |
| Charbel Haber | M | - | 3 Jahre | |
| Sanjay Jariwala | M | - | 2 Jahre | |
| Maria Castresana | F | - | 3 Jahre | |
| Thomas-Christian Mix | M | 57 | 1 Jahre | |
| Vanya Sagar | F | 49 | 3 Jahre | |
| Yue Hong Qian | M | 60 |
École Normale Supérieure
| 3 Jahre |
| Karoline Shair | M | - | 2 Jahre | |
| Janice Olson | F | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Charles Monahan | M | - |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 4 Jahre |
| Katharina Kreymborg | M | - | 1 Jahre | |
| David W Miller | M | - | 7 Jahre | |
| Franois Bastin | M | 52 |
École Normale Supérieure
| 4 Jahre |
| Nithya Desikan | F | - | 1 Jahre | |
| Gavin Malenfant | M | 61 | 1 Jahre | |
| Catherine Steele | F | - | 1 Jahre | |
| John Koconis | M | 54 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
| Burt Adelman | M | 71 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 2 Jahre |
| Stewart Craig | M | 63 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 2 Jahre |
| Brian Schwab | M | 59 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 3 Jahre |
| Christophe Bureau | M | 57 |
École Normale Supérieure
| 1 Jahre |
| Jean-Sébastien Cleiftie | M | 50 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 5 Jahre |
| Sam Hall | M | 42 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 4 Jahre |
| Timothy Kelly | M | 55 | - | |
| Camille Lee | F | - | 1 Jahre | |
| Joan Nickerson | F | 56 | 5 Jahre | |
| Arnim Helmboldt | M | - |
École Normale Supérieure
| 3 Jahre |
| Mario David Saltarelli | M | 63 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Jens Holstein | M | 60 | 9 Jahre | |
| Amy Chevalier Efantis | F | - | - | |
| Aaron Kantoff | M | 29 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 4 Jahre |
| Delphine Grison | M | 55 |
École Normale Supérieure
| 4 Jahre |
| Michael Panzara | M | 57 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 7 Jahre |
| Jacques Le Pape | M | 56 |
École Normale Supérieure
| 4 Jahre |
| Steven Avruch | M | 63 | 4 Jahre | |
| David Ford | M | 56 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 1 Jahre |
| Sung Lee | M | 53 | 2 Jahre | |
| Joan Wood | F | - | 2 Jahre | |
| Anca Alexandru | M | - | - | |
| Alexander Scheer | M | 61 |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | 4 Jahre |
| Catherine Stehman-Breen | M | 61 | - | |
| Noomane Fehri | M | - |
École Normale Supérieure
| 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 49 | 49,00% |
| Deutschland | 32 | 32,00% |
| Frankreich | 20 | 20,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jean-Paul Kress
- Persönliches Netzwerk
